Partners Grp Pvt Eqt Partners Grp E-PEYS - NAV increased by 0.5% in January

Partners Private Equity

07/03/2025 07:00

RNS Number : 8001Z

Partners Group Private Equity Ltd

07 March 2025

 

(LSE: PEYS/PEY)

 

Partners Group Private Equity Limited

 

NAV increased by 0.5% in January

 

 

·    NAV increased by 0.5% to EUR 1'044.1 million corresponding to EUR 15.10 per share

·    Positive value creation (0.8%), slightly offset by currency movements (-0.3%)

·    PGPE Ltd invested EUR 2.2 million during the reporting period

 

From the total EUR 2.2 million invested by PGPE Ltd in January, EUR 1.6 million was in Avid Bioservices ("Avid"), a US-based biologics contract development and manufacturing organization ("CDMO") specializing in small-batch production of complex mammalian proteins. Founded in 1981, Avid transitioned to a CDMO model in 2018 and now operates four facilities in California with over 370 employees. The company has a strong reputation in a niche sector and benefits from robust organic growth and revenue visibility. Partners Group has strong conviction in CDMOs, having tracked such companies for several years now as part of the firm's thematic research under the Health & Life vertical.

 

At the portfolio level, KinderCare Learning Companies ("KinderCare") and Galderma, both of which began trading on the public market in 2024, were the top contributors to value creation during the month. The largest for-profit provider of early childhood education and care services in the US released the "2025 KinderCare CHRO Perspectives Survey", conducted by the Harris Poll. The report highlights human resources leaders' recognition of the critical role childcare benefits play in talent acquisition, retention, and employee well-being, while underscoring the urgent need for more flexible and customizable options.

 

Further, Galderma, a pure-play dermatology category leader, recently, announced the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025, including treatments for frown lines (Relfydess), facial filler (Restylane), and biostimulator (Sculptra). Meanwhile, Nemluvio (nemolizumab) has received marketing authorization in the UK and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis.

 

 

Further information is available in the monthly report, which can be accessed via: https://www.partnersgroupprivateequitylimited.com/en/investor-relations/financial-reports

 

Ends.

 

About Partners Group Private Equity Limited

PGPE Ltd (formerly Princess Private Equity Holding Limited) is an investment holding company founded in 1999 and domiciled in Guernsey. It invests in private equity direct investments. PGPE Ltd is managed in its investment activities by Partners Group, a global private markets investment management firm with over USD 150 billion in investment programs under management in private markets, of which USD 78 billion is in private equity. Partners Group itself is listed at the Swiss Stock Exchange (ticker: PGHN).  PGPE Ltd aims to provide shareholders with long-term capital growth and an attractive dividend yield. PGPE Ltd is traded on the Main Market of the London Stock Exchange (ticker: PEY for the Euro Quote; PEYS for the Sterling Quote).

 

Contacts

Partners Group Private Equity Limited:

pgpe-ltd@partnersgroup.com

www.partnersgroupprivateequitylimited.com

 

Investor relations contact:
Andreea Mateescu
Phone: +41 41 784 66 73
E-mail: andreea.mateescu@partnersgroup.com
Media relations contact:
Jenny Blinch
Phone: +41 41 784 65 26
E-mail: jenny.blinch@partnersgroup.com

 

Registered Number: 35241   LEI: 54930038LU8RDPFFVJ57

Notes:

1.     Note that references in this announcement to Partners Group Private Equity Limited have been abbreviated to "PGPE Ltd" or "Company". References to Partners Group AG have been abbreviated to "Partners Group" or "Investment Manager".

2.     This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Partners Group Private Equity Limited. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein is not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.

3.   This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of PGPE Ltd' website nor the contents of any website accessible from hyperlinks on PGPE Ltd' website (or any other website) is incorporated into, or forms part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
STRPKOBDABKKKNK